



February 28, 2017

## **Ocera to Present at the Cowen and Company 37th Annual Healthcare Conference**

### **Company Presentation Scheduled for March 8, 2017 at 11:20 AM ET**

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming Cowen and Company 37<sup>th</sup> Annual Healthcare Conference being held March 6-8, 2017 at The Boston Marriott Copley Place in Boston, Massachusetts. Ocera's presentation will take place on March 8, 2017 at 11:20 AM Eastern Time.

A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, [www.ocerainc.com](http://www.ocerainc.com). A replay of the presentation will be available for 60 days following the conference for those unable to listen live.

### **About Ocera**

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see [www.ocerainc.com](http://www.ocerainc.com).

OCRX-G

### **Contact:**

Susan Sharpe  
Ocera Therapeutics, Inc.  
[contact@ocerainc.com](mailto:contact@ocerainc.com)  
919-328-1109